FCER1G

CAMBRIDGE, Mass., April 17, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company, today announced its presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting, being held in Orlando, Florida. "At AACR 2023, we are pleased to present late-breaking research on our in vivo engineering capabilities and clinical data from our Phase I IMAGINE study of MT-101 in PTCL patients," said Daniel Getts, Ph.D., Chief Executive Officer of Myeloid. "These data demonstrate the power of myeloid cells to orchestrate broad immune responses. We look forward to advancing our platform and expanding our clinical portfolio of in vivo programming candidates and ATAK™ CAR cell therapy candidates." Details of the poster presentations are below: Title: "In vivo delivery of novel CD89 fusion receptor to myeloid cells by mRNA activates anti-tumor immunity " Session: Late-Breaking Research: Experimental and Molecular Therapeutics 1 Session Date and Time: Sunday April 16, 2023, 1:30 PM - 5:00 PM Location: Poster Section 35 Poster Board Number: 19 Abstract Presentation Number: LB027 Abstract Highlights: Myeloid illustrates with this poster its ability to engineer circulating and tumor-penetrating myeloid cells so that these cells are activated within the tumor setting and elicit anti-tumor adaptive immunity. This approach is an attractive, novel manner to harness systemic anti-tumor immunity. Myeloid has applied its engineering insights to overcome challenges of specifically targeting and activating myeloid cells in vivo. Myeloid has developed a novel in vivo myeloid cell engineering platform, in which a chimeric antigen receptor (CAR) is generated by fusing a tumor recognition scFv with the alpha chain of human Fc receptors (CD89). The stable expression and function of these receptors requires the endogenously expressed common Fc receptor gamma chain (FcRg), which expression is mostly restricted to myeloid cells. For in vivo engineering, the construct is encapsulated and delivered in lipid nanoparticles (LNP). Myeloid's most-advanced in vivo programming candidate is a candidate referred to as MT-302, targeting trophoblast cell surface antigen 2 (TROP2) on cancer cells. TROP2 is overexpressed in most human solid epithelial cancers, as compared to low expression in corresponding normal tissue. Increased TROP2 expression has been linked to increased tumor growth and has been implicated as a prognostic marker in these cancers, supporting the development of earlier therapies targeting TROP2. Within immunodeficient xenograft models of hepatocellular carcinoma and triple negative breast cancer, delivery of LNP mRNA encoding GPC3-CD89 or TROP2-CD89 fusion proteins resulted in anti-tumor efficacy, confirming the ability of this approach to program myeloid cells. Repeat dosing studies showed significant anti-tumor efficacy following bi-weekly administration of TROP2-CD89. These studies highlight the potential of in vivo delivery of CD89 fusion proteins to program myeloid cells to recognize and kill cancer, thus providing a novel, promising approach to treating cancer. Title: "Initial Preclinical and Clinical Experience of Autologous Engineered Monocytes in T cell Lymphoma Patients" Session Category: Clinical Trials Session: Phase I Clinical Trials in Progress Session Date and Time: Monday April 17, 2023, 1:30 PM - 5:00 PM Location: Poster Section 46 Poster Board Number: 19 Published Abstract Number: CT131 Abstract Highlights: Myeloid developed the first engineered monocyte cell product, by engineering autologous monocytes to express a novel chimeric antigen receptor (CAR). This CAR contains a tumor recognition domain that is fused to a CD8 hinge domain, Fcγ and PI3K intracellular signaling domains. In addition to imparting tumor specificity, the Fcγ and PI3K signaling domains promote phagocytosis, cytokine production and antigen presentation upon activation. In a rodent model of melanoma (gp75+ B16/F10-OVA), Ly6C+ monocytes engineered with this receptor were able to phagocytose tumor cells and cross present antigen in vitro. In vivo infusion of engineered monocytes was associated with significant suppression of tumor growth. FACS analysis of tumor-infiltrates demonstrated that engineered monocytes preferentially infiltrated tumors and differentiated into antigen presenting cells. Based on these promising data, MT-101 is being assessed in humans in the Phase 1, open-label, first-in-human trial in patients with refractory or relapsed T cell lymphoma, IMAGINE trial (NCT05138458). The primary objective is the assessment of safety and tolerability at Day 28, following 3 weekly cycles of 2 infusions. Secondary objectives include assessment of correlative markers of response, pharmacokinetics, and efficacy. In the first 3 subjects, MT-101 was well-tolerated, with no evidence of CRS, ICANS, or infusion reactions. Examination of biomarkers by CyTOF in one subject showed changes in circulating leukocytes, including B cells. In this subject, survival has been greater than 10 months, while the median overall survival of patients with R/R PTCL is 5.5 months. Abstracts and full session details can be accessed through the AACR meeting planner: AACR Annual Meeting 2023 | Meetings | AACR. About Myeloid's ATAK™ CAR receptors and in vivo mRNA Programming Myeloid's novel class of CARs, known as ATAK™ Receptors, combine tumor recognition with multiple proprietary innate-immune signaling domains. Myeloid scientists have screened multiple unexplored combinations of innate-immune signals and uncovered optimal multi-signal pathways. The combination of cancer recognition binders with these novel intracellular signaling domains allows myeloid cells to be reprogrammed with previously unexplored combinations of immune signals, leading to tumor killing and broad systemic anti-tumor responses. Myeloid's novel in vivo engineering platform specifically targets and activates myeloid cells to elicit broader anti-tumor adaptive immunity. Through this approach, Myeloid demonstrates that delivery of lipid-nanoparticles (LNPs) encapsulating mRNA results in selective uptake and expression by myeloid cells in vivo, leading to potent tumor killing in multiple cold tumor models. These data demonstrate the potential for Myeloid's technology to program cells directly in vivo. About Myeloid Therapeutics Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases. Integrating the fields of RNA, immunology and medicine, the Company's proprietary platform provides clinical solutions by matching therapeutic modalities to disease conditions, including use of autologous cell therapies, in vivo cell programming using mRNA, RNA-based gene-editing using RetroT™ and multi-targeted biologics. For more information, visit . Investor and Media Contact Amy Conrad Juniper Point [email protected] SOURCE Myeloid Therapeutics

- 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant - EOS-984, a first-in-class program targeting a new mechanism of action in the adenosine pathway, expected to enter clinical studies in mid-2023 - Cash and investment balance of $731.4MM as of December 31, 2022, expected to provide runway into 2026 WATERTOWN, Mass. and GOSSELIES, Belgium, March 15, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2022. "Building off a successful year of execution in 2022, we continue to advance our robust portfolio of programs through multiple trials with strong financial resources that are expected to provide cash runway into 2026," said Michel Detheux, Ph.D., president, and chief executive officer of iTeos. "Alongside our valued partner GSK, we aim to make significant progress in 2023 in our broad and differentiated development plan for EOS-448, our anti-TIGIT antibody. This includes executing two Phase 2 studies of the doublet with GSK’s anti-PD-1, Jemperli (dostarlimab) and clinical progress with novel triplets. We also remain on track to launch upcoming pivotal trials of EOS-448 in combination with dostarlimab.” Continued Dr. Detheux, “We are progressing in our efforts to unlock the potential of the adenosine pathway. We believe that through our differentiated inupadenant program and unique and targeted approach, we are positioned for success in this important mechanism of immunosuppression. We continue to assess our proprietary biomarker for indication and patient selection. We are encouraged by the recently disclosed monotherapy response, which we are pleased to see is now a confirmed partial response, in a patient who had the highest level of the biomarker that we have recorded to date. We have decided to prioritize development of inupadenant in our ongoing study in combination with platinum-doublet chemotherapy in patients with chemo-naïve NSCLC as we have determined that the post-PD-1 melanoma setting is not a path to accelerated approval. This is consistent with our disciplined investment approach, and we continue to focus our internal resources and capital on our most promising discovery and development programs.” Clinical Development PlansEOS-448/GSK4428859A: IgG1 anti-TIGIT monoclonal antibody designed to engage the Fc gamma receptor (FcγR) and enhance the anti-tumor response through multifaceted mechanisms. In collaboration with GSK, iTeos is evaluating EOS-448 as a potential next-generation immuno-oncology agent in multiple combination studies. Highlights include: Ongoing randomized Phase 2 trial assessing the doublet of dostarlimab with EOS-448 in previously untreated advanced / metastatic non-small cell lung cancer (NSCLC).Ongoing Phase 2 expansion study assessing the doublet of dostarlimab with EOS-448 in 1L advanced or metastatic head and neck squamous cell carcinoma.Continued exploration of two novel triplets in selected advanced solid tumors both in Phase 1b trials: EOS-448 with dostarlimab and GSK’s investigational anti-CD96 antibody, and EOS-448 with dostarlimab and GSK’s investigational anti-PVRIG antibody. Advancement of the monotherapy dose escalation part of a Phase 1/2 trial evaluating EOS-448 as both a monotherapy and in combination with Bristol Myers Squibb’s iberdomide in multiple myeloma. Adenosine PathwayInupadenant (EOS-850): Designed as an insurmountable and highly selective small molecule antagonist of the adenosine A2A receptor, the only high-affinity adenosine receptor expressed on multiple immune cells found in the tumor microenvironment. Highlights include: Enrolling in the dose ranging part (Part 1) of an ongoing two-part Phase 2 trial in post-IO metastatic non-squamous NSCLC to evaluate the combination of inupadenant with platinum-doublet chemotherapy compared to standard platinum-doublet chemotherapy.Completed enrollment in the biomarker-high cohort evaluating inupadenant as a monotherapy in patients with advanced solid tumors selected for high biomarker expression.Completed enrollment in the Phase 2a trial evaluating inupadenant in combination with pembrolizumab in post-PD-1 melanoma.Confirmed partial response using inupadenant in monotherapy in a patient who had the highest level of the biomarker that we have recorded to date.iTeos will present a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place from April 14-19, 2023, in Orlando, Florida. The poster presentation will further explore the biomarker findings and highlight a new mechanism of action of inupadenant based on the evaluation of tumor biopsies from treated patients and additional translational work. EOS-984: First-in-class small molecule program targeting a novel mechanism in the adenosine pathway. This clinical development program has the potential to fully reverse the profound immunosuppressive action of adenosine on T and B cells. EOS-984 effects have been shown preclinically to be enhanced by combining with inupadenant and other standards of care.The company completed Investigational New Drug / Clinical Trials Application-enabling activities including toxicity studies and anticipates initiating clinical studies for EOS-984 in mid-2023. Fourth Quarter and Full Year 2022 Financial Results Cash and Investment Position: The Company’s cash, cash equivalents and investments position was $731.4 million as of December 31, 2022, as compared to $848.5 million of cash and cash equivalents as of December 31, 2021. The Company continues to expect its cash and investment position to provide runway into 2026.Research and Development (R&D) Expenses: R&D expenses were $25.4 million for the fourth quarter and $97.4 million for the year ended December 31, 2022, as compared to $17.4 million for the fourth quarter and $59.4 million for the year ended December 31, 2021. The increase was primarily due to an increase in activities related to EOS-448 and inupadenant clinical trials.General and Administrative (G&A) Expenses: G&A expenses were $11.1 million for the fourth quarter and $43.9 million for the year ended December 31, 2022, as compared to $9.6 million for the fourth quarter and $40.5 million for the ended December 31, 2021. The increase was primarily due to an increase in headcount and related costs and an increase in stock-based compensation compared to the prior year. This increase was partially offset by decreases in legal and other professional fees compared to the prior year.Net Income/Loss: Net income attributable to common shareholders was $20.5 million, or a net income of $0.57 per basic share and $0.54 of per diluted share, for the quarter ended December 31, 2022, as compared to a net income of $184.9 million, or a net income of $5.24 per basic share and $4.88 per diluted share, for the quarter ended December 31, 2021. Net income was $96.7 million, or net income of $2.72 per basic share and $2.56 per diluted share, for the year ended December 31, 2022, as compared to a net income of $214.5 million, or a net income of $6.10 per basic share and $5.68 per diluted share, for the year ended December 31, 2021. About iTeos Therapeutics, Inc.iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression, into proof-of-concept trials in several indications following encouraging single-agent activity in Phase 1. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium. Internet Posting of InformationiTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos. Forward-Looking StatementsThis press release contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the potential benefits of EOS-448, inupadenant and EOS-984; our expectations regarding the anticipated development of our pipeline of candidates; our goal to make significant progress in 2023 in our broad and differentiated development plan for EOS-448, including two Phase 2 studies of the doublet with GSK’s dostarlimab and clinical progress with novel triplets; iTeos remaining on track to launch upcoming pivotal trials of EOS-448 in combination with dostarlimab; iTeos being positioned for success in its adenosine pathway programs; the expectation that EOS-984 will enter clinical studies in mid-2023; and the expectation to have cash runway into 2026. These forward-looking statements involve risks and uncertainties, many of which are beyond iTeos’ control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: market conditions; the expected benefits and opportunities related to the agreement between iTeos and GSK may not be realized or may take longer to realize than expected due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement, challenges and uncertainties inherent in product research and development and manufacturing limitations; iTeos may encounter unanticipated costs or may expend cash more rapidly or more slowly than currently anticipated due to challenges and uncertainties inherent in product research and development and biologics manufacturing; success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; the data for our product candidates may not be sufficient for obtaining regulatory approval to move into later stage trials or to commercialize products; iTeos may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of iTeos’ control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates and the impact of the COVID-19 pandemic; and those risks identified under the heading “Risk Factors” in iTeos’ Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review. Statements regarding the Company’s cash runway do not indicate when the Company may access the capital markets. Any of the foregoing risks could materially and adversely affect iTeos’ business, results of operations and the trading price of iTeos’ common stock. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. iTeos does not undertake any obligation to publicly update its forward-looking statements other than as required by law. For further information, please contact: Investor Contact:Ryan BakeriTeos Therapeutics, Inc.Ryan.Baker@iteostherapeutics.com Media Contact:media@iteostherapeutics.com

New instrument provides greater sensitivity to enable additional applications for discovery and characterization of novel therapeutics with unrivalled throughput and efficiency SALT LAKE CITY, Utah--(BUSINESS WIRE)-- Carterra Inc., the world leader in innovative technologies enabling high-throughput biology, launched its latest HT-SPR instrument, the LSAXT, at the Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition in San Diego, CA. The LSAXT brings augmented sensitivity to Carterra’s highly successful LSA platform enabling additional applications throughout drug discovery and development at throughput levels unseen in any other instrument. Carterra will be showcasing the new LSAXT platform for high-throughput SPR at the SLAS event (booth 2127) with a launch program that includes a user presentation by Dragonfly Therapeutics on February 27 at 2:00 pm. The LSAXT instrument boasts additional hardware and software features that build upon the capabilities of Carterra’s original and highly successful LSA instrument while maintaining its impressive throughput and sample efficiency. The LSA delivers 100 times the data in 10% of the time-to-answer and uses 1% of the sample required by other label-free platforms. The LSAXT enables an expanded range of applications that include some of the most exciting and growing areas in drug discovery such as proteolysis-targeting chimeras (PROTAC®s), membrane proteins, DNA-Encoded Library (DEL) compounds, and rapid kinetic systems such as cytokines, protein-protein inhibitors, and Fc gamma receptors. Additionally, the increased performance in the LSAXT allows measurement of lower molecular weight analytes including kinase inhibitors. Since its launch in 2018, Carterra’s LSA antibody discovery and characterization platform has penetrated 19 of the largest 20 pharmaceutical companies, CROs, and biotechs on four continents. Characterizing binding kinetics and epitope coverage of large numbers of antibodies early in the drug discovery process has been transformative. The speed at which antibodies can now be identified and characterized as candidate therapeutics has vastly improved compared to traditional methods. The LSA platform has been profiled in multiple Science, Nature, and Cell peer-reviewed papers, one of which profiled the development of a novel monoclonal antibody therapeutic, bamlanivimab, which was the world’s first COVID-19 therapeutic and the fastest biologic ever to reach clinical trials thanks to Eli Lilly and AbCellera. At SLAS, scientists from Dragonfly Therapeutics will discuss the benefits of running the Fc gamma receptor (FcγR) binding application which is a critical component of ADCC, ADCP, and CDC and an important feature to measure in Fc-containing molecules. Data will be presented showcasing the ability to characterize a full panel of biotinylated FcγRs now possible with the Carterra LSAXT’s throughput and greater flexibility, resulting in significantly faster time to results and sample efficiency than currently available 8-channel biosensor instruments in the market. Speaking about the launch of the LSAXT at SLAS 2023, Christopher Silva, Vice President of Marketing and Product at Carterra added, “This is a great day for biologics discovery scientists and for Carterra. You always run the risk of missed expectations when you launch a follow-on product after a game changer like the LSA. But we’ve proved that with the LSAXT the story only gets better for us and our customers.” About Carterra, Inc. Carterra® is privately held and is the leading provider of high-throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates. Carterra’s LSA® instrument, software, and consumables for biotherapeutic discovery and characterization deliver up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample required by other systems. The LSA combines patented microfluidics technology with real-time high-throughput Surface Plasmon Resonance (HT-SPR) and industry-leading data analysis and visualization software to revolutionize mAb screening. The new LSAXT provides enhanced optics to enable additional applications in biotherapeutic discovery and characterization. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, PerkinElmer. For additional information, please visit .